Navigation Links
The Galien Foundation Celebrates Biomedical Innovation in Fourth Galien Forum
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire/ -- The Galien Foundation today announced the formal program of presenters and panels for its Fourth Galien Forum, scheduled for Tuesday, October 22, 2013 at the Alexandria Life Sciences Center in New York City.  The Galien Forum, conducted in conjunction with the prestigious Prix Galien Awards, features roundtable debates focusing on critical, global healthcare issues and challenges.  This year's program includes a panel of current industry CEOs tackling the impact of the Affordable Care Act on the biopharmaceutical industry: Ken Frazier (Merck), Alex Gorsky (Johnson & Johnson) and Dr. John Lechleiter (Eli Lilly & Company), moderated by P. Roy Vagelos, M.D. (Chairman of Regeneron Pharmaceuticals and retired Chairman and CEO at Merck).

(Logo: http://photos.prnewswire.com/prnh/20130709/NY43872LOGO )

The Keynote Session will be offered by the renowned Bert Vogelstein, M.D., Professor of Oncology and Pathology, Investigator, Howard Hughes Medical Institute; Director, Ludwig Center for Cancer Genetics & Therapeutics at Johns Hopkins School of Medicine. Long recognized as a "giant of science…whose work has been most influential over the past 20 years," according to The Guardian, Dr. Vogelstein explores the genetic causes of cancer.

Joel S. Marcus, Chairman, Alexandria and Neil de Crescenzo, General Manager, Oracle Health Sciences, long-time supporters of the Galien Foundation mission, will welcome participants.

"In this our Fourth Galien Forum, we are again so honored to have attracted biopharmaceutical leaders, researchers, clinicians and health policy experts at the very top of their fields to contribute their expertise and wisdom to our program," commented Bruno Cohen, Galien Foundation Chairman.  "These annual dialogues continue to demonstrate that it is only through coming together for conversations and working collaboratively that we will be able to address the challenging global healthcare issues facing scientific, medical and technological innovation."

This year, The Galien Forum explores the need for and challenges facing enhanced Industry-academia interactions in a panel including:

  • Dr. Christopher Austin, Director, National Center for Advancing Translational Sciences – National Institutes of Health
  • Dr. Michael S. Brown, Regental Professor, University of Texas Southwestern Medical Center
  • Dr. Robert M. Califf, Vice Chancellor for Clinical and Translational Medicine, Duke University
  • Dr. John Thomas Potts, Jr., Neuroendocrine Clinical Center, Harvard Medical Scholl
  • Dr. Michael Rosenblatt, Executive Vice President and Chief Medical Officer, Merck, who will serve as panel moderator.

The Galien Foundation also disclosed today that nomination submissions for the 2013 Prix Galien USA Awards are actively continuing, with final candidates to be announced shortly.  The Prix Galien Awards represent the highest accolade for research and development – the biomedical industry's equivalent of the Nobel Prize.

"The focus of biomedical innovation must be major improvement in the patient's welfare: prolongation of life, less need for hospitalization, quality of life, ability to continue normal life activities," commented P. Roy Vagelos, M.D., Chairman of Regeneron Pharmaceuticals, retired Chairman and Chief Executive Officer of Merck and chair of the Prix Galien USA Awards Committee.  "Interdisciplinary collaborations starting with target identification, product discovery and candidate selection, clinical characterization and product launch all pull together the full strengths of the industry to improve outcomes for patients.  Real success is improved patient health and ultimately decreased health care costs."

About the Galien Foundation and the Prix Galien Awards

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information visit www.galienfoundation.org.

Galien Foundation Media Contact:
Jon Florio
Makovsky
jflorio@makovsky.com
212-508-9667

 


'/>"/>
SOURCE Galien Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
3. The Sidney Kimmel Foundation for Cancer Research Announces 2013 Grant Recipients
4. OU professor recipient of grant from the Simons Foundation Fellows Program in Theoretical Physics
5. The Research Foundation for The State University of New York Enters Site License Agreement with 2Market Information Inc., Publisher of Technology Transfer Tactics
6. Wysebridge Patent Bar Review Supports the National Foundation for Celiac Awareness (NFCA) During Celiac Awareness Month
7. Save The Cord Foundation, a Global Leader in Cord Blood Advocacy, Announces its Expansion of Educational Information Surrounding Other Non-Controversial Stem Cell Sources
8. Coulter Foundation Surprises Westminster College With One Million Dollar Gift
9. Research Foundations Collaborate To Fund Phase 1 Study Of Cancer Drug In Alzheimers Disease Patients
10. Keystone Symposia Announces Grant from Alfred P. Sloan Foundation for an Advanced Life Sciences Training Program
11. Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):